Literature DB >> 25142214

Chronic passive venous congestion drives hepatic fibrogenesis via sinusoidal thrombosis and mechanical forces.

Douglas A Simonetto1, Hui-yin Yang, Meng Yin, Thiago M de Assuncao, Jung Hee Kwon, Moira Hilscher, Shuchong Pan, Liu Yang, Yan Bi, Arthur Beyder, Sheng Cao, Robert D Simari, Richard Ehman, Patrick S Kamath, Vijay H Shah.   

Abstract

UNLABELLED: Chronic passive hepatic congestion (congestive hepatopathy) leads to hepatic fibrosis; however, the mechanisms involved in this process are not well understood. We developed a murine experimental model of congestive hepatopathy through partial ligation of the inferior vena cava (pIVCL). C57BL/6 and transgenic mice overexpressing tissue factor pathway inhibitor (SM22α-TFPI) were subjected to pIVCL or sham. Liver and blood samples were collected and analyzed in immunohistochemical, morphometric, real-time polymerase chain reaction, and western blot assays. Hepatic fibrosis and portal pressure were significantly increased after pIVCL concurrent with hepatic stellate cell (HSC) activation. Liver stiffness, as assessed by magnetic resonance elastography, correlated with portal pressure and preceded fibrosis in our model. Hepatic sinusoidal thrombosis as evidenced by fibrin deposition was demonstrated both in mice after pIVCL as well as in humans with congestive hepatopathy. Warfarin treatment and TFPI overexpression both had a protective effect on fibrosis development and HSC activation after pIVCL. In vitro studies show that congestion stimulates HSC fibronectin (FN) fibril assembly through direct effects of thrombi as well as by virtue of mechanical strain. Pretreatment with either Mab13 or Cytochalasin-D, to inhibit β-integrin or actin polymerization, respectively, significantly reduced fibrin and stretch-induced FN fibril assembly.
CONCLUSION: Chronic hepatic congestion leads to sinusoidal thrombosis and strain, which in turn promote hepatic fibrosis. These studies mechanistically link congestive hepatopathy to hepatic fibrosis.
© 2014 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25142214      PMCID: PMC4303520          DOI: 10.1002/hep.27387

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  37 in total

1.  The morphology and pathogenesis of cardiac fibrosis of the liver.

Authors:  E MOSCHCOWITZ
Journal:  Ann Intern Med       Date:  1952-04       Impact factor: 25.391

2.  The liver in heart failure; relation of anatomical, functional, and circulatory changes.

Authors:  S SHERLOCK
Journal:  Br Heart J       Date:  1951-07

3.  Recombinant human tissue factor pathway inhibitor as a possible anticoagulant targeting hepatic sinusoidal walls.

Authors:  F Yamanobe; S Mochida; A Ohno; K Ishikawa; K Fujiwara
Journal:  Thromb Res       Date:  1997-03-15       Impact factor: 3.944

4.  Centrilobular and perisinusoidal fibrosis in experimental congestive liver in the rat.

Authors:  H Akiyoshi; T Terada
Journal:  J Hepatol       Date:  1999-03       Impact factor: 25.083

Review 5.  Tissue factor pathway inhibitor: structure, biology and involvement in disease.

Authors:  Bashir A Lwaleed; Paul S Bass
Journal:  J Pathol       Date:  2006-02       Impact factor: 7.996

6.  Low molecular weight heparin prevents hepatic fibrogenesis caused by carbon tetrachloride in the rat.

Authors:  Wataru Abe; Kenichi Ikejima; Tie Lang; Kyoko Okumura; Nobuyuki Enomoto; Tsuneo Kitamura; Yoshiyuki Takei; Nobuhiro Sato
Journal:  J Hepatol       Date:  2006-10-25       Impact factor: 25.083

7.  Accumulation and cellular localization of fibrinogen/fibrin during short-term and long-term rat liver injury.

Authors:  K Neubauer; T Knittel; T Armbrust; G Ramadori
Journal:  Gastroenterology       Date:  1995-04       Impact factor: 22.682

8.  Role of thrombosis in the pathogenesis of congestive hepatic fibrosis (cardiac cirrhosis).

Authors:  I R Wanless; J J Liu; J Butany
Journal:  Hepatology       Date:  1995-05       Impact factor: 17.425

Review 9.  Modulation of cell-extracellular matrix interactions.

Authors:  J L Sechler; S A Corbett; M B Wenk; J E Schwarzbauer
Journal:  Ann N Y Acad Sci       Date:  1998-10-23       Impact factor: 5.691

10.  Fibronectin provides a conduit for fibroblast transmigration from collagenous stroma into fibrin clot provisional matrix.

Authors:  D Greiling; R A Clark
Journal:  J Cell Sci       Date:  1997-04       Impact factor: 5.285

View more
  49 in total

1.  Ultrasound Elastography and MR Elastography for Assessing Liver Fibrosis: Part 2, Diagnostic Performance, Confounders, and Future Directions.

Authors:  An Tang; Guy Cloutier; Nikolaus M Szeverenyi; Claude B Sirlin
Journal:  AJR Am J Roentgenol       Date:  2015-04-23       Impact factor: 3.959

2.  Budd-Chiari syndrome: a focussed and collaborative approach.

Authors:  Amar Mukund; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2018-10-08       Impact factor: 6.047

3.  Redefining Budd-Chiari syndrome: A systematic review.

Authors:  Naomi Shin; Young H Kim; Hao Xu; Hai-Bin Shi; Qing-Qiao Zhang; Jean Paul Colon Pons; Ducksoo Kim; Yi Xu; Fei-Yun Wu; Samuel Han; Byung-Boong Lee; Lin-Sun Li
Journal:  World J Hepatol       Date:  2016-06-08

Review 4.  Vascular liver diseases on the clinical side: definitions and diagnosis, new concepts.

Authors:  Dominique-Charles Valla; Dominique Cazals-Hatem
Journal:  Virchows Arch       Date:  2018-03-24       Impact factor: 4.064

5.  Mechanotransduction-modulated fibrotic microniches reveal the contribution of angiogenesis in liver fibrosis.

Authors:  Longwei Liu; Zhifeng You; Hongsheng Yu; Lyu Zhou; Hui Zhao; Xiaojun Yan; Dulei Li; Bingjie Wang; Lu Zhu; Yuzhou Xu; Tie Xia; Yan Shi; Chenyu Huang; Wei Hou; Yanan Du
Journal:  Nat Mater       Date:  2017-11-13       Impact factor: 43.841

6.  Chronic liver injury drives non-traditional intrahepatic fibrin(ogen) crosslinking via tissue transglutaminase.

Authors:  L G Poole; A Pant; K S Baker; A K Kopec; H M Cline-Fedewa; S E Iismaa; M J Flick; J P Luyendyk
Journal:  J Thromb Haemost       Date:  2018-12-10       Impact factor: 5.824

Review 7.  Evolution in the understanding of the pathophysiological basis of portal hypertension: How changes in paradigm are leading to successful new treatments.

Authors:  Jaume Bosch; Roberto J Groszmann; Vijay H Shah
Journal:  J Hepatol       Date:  2015-04       Impact factor: 25.083

8.  Hepatic Stellate Cell Selective Disruption of Dynamin-2 GTPase Increases Murine Fibrogenesis through Up-Regulation of Sphingosine-1 Phosphate-Induced Cell Migration.

Authors:  Ruisi Wang; Qian Ding; Thiago M De Assuncao; Taofic Mounajjed; Jessica L Maiers; Changwei Dou; Sheng Cao; Usman Yaqoob; Robert C Huebert; Vijay H Shah
Journal:  Am J Pathol       Date:  2016-11-10       Impact factor: 4.307

9.  HDL activation of endothelial sphingosine-1-phosphate receptor-1 (S1P1) promotes regeneration and suppresses fibrosis in the liver.

Authors:  Bi-Sen Ding; Catherine H Liu; Yue Sun; Yutian Chen; Steven L Swendeman; Bongnam Jung; Deebly Chavez; Zhongwei Cao; Christina Christoffersen; Lars Bo Nielsen; Susan R Schwab; Shahin Rafii; Timothy Hla
Journal:  JCI Insight       Date:  2016-12-22

Review 10.  Role of the blood coagulation cascade in hepatic fibrosis.

Authors:  Asmita Pant; Anna K Kopec; James P Luyendyk
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-05-03       Impact factor: 4.052

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.